Stanislas VEILLET – Chairman
Stanislas Veillet set up Biophytis in September 2006. He had previously held a number of posts in the fields of medical research, nutrition and functional foods, in particular with Danone, Pharmacia-Monsanto and Cargill. Stanislas has a doctorate in genetics, graduated in engineering from Agro ParisTech and is author of a dozen patents.
Eric Rowinsky is a medical doctor focused on the comprehensive development and registration strategies of cancer therapeutics of all types. He also has extensive teaching experience, notably at the Johns Hopkins University School of Medicine. Since 2015, he has served as an Executive Director and President at Rgenix, a life sciences company focused on discovering new cancer targets using a novel microRNA platform licensed, as well as the Chief Scientific Director of Clearpath Development. He also sits on the Board of Directors or the Scientific Board of several private or listed companies such as Biogen Inc or Fortress Biotech. He is also Editor-in-Chief of Investigational New Drug and has published around 315 manuscripts in both the nonclinical and clinical research fields.
Jean-Gérard Galvez spent most of his career in the United States managing high-tech and life sciences businesses. He started as an engineer with Dupont de Nemours and continued in American IT groups, such as Control Data and Banctec serving as President of subsidiaries and International Vice-President. Jean-Gérard joined ActivCard in 1995, a start-up of French origin, as President and CEO. The company was floated on the Nasdaq in 2000, raising US $300 million on a market capitalization of US $2,000 million. Since his return to France in 2006, Jean-Gérard Galvez has sat on the Board of directors of numerous companies. He is an engineering graduate of the Institut National Polytechnique de Nancy, has a DEA in management and an MBA from the Stanford Executive Program.
Ms. Franchi spent more than 20 years building and leading senior corporate and divisional financial teams in the public and private pharmaceutical, biotech, and diagnostics sectors. Ms. Franchi joins the board of directors having experience as Chief Financial Officer at Dimension Therapeutics and Good Start Genetics. She is currently CFO at Merrimack, a biotechnology company specializing in oncology and listed on the Nasdaq. Previously, Ms. Franchi spent 16 years at Genzyme Corporation, where she held roles of increasing responsibility and was instrumental in preparing the company for its transition from early market introductions to becoming the industry leader in rare disease drug development and commercialization. Ms. Franchi received her B.A. degree from Hofstra University.
An HEC graduate, Nadine Coulm started her career with Banque Paribas before joining the Danone Group where she was notably international treasurer, purchasing control director, divisional finance director and Head of Investor Relations. In 2006, she was appointed to director of financial communication for the Casino group. From January 2013, she served as director of investor relations and financing for the Fnac group, for whom she managed the stock market flotation. Nadine, is currently head of financing and investor relations of Korian, a listed European group specializing in support services for elderly people. She is also a member of the Femmes Business Angels network for which she has been administrator since June 2014.
Dimitri Batsis is a successful entrepreneur who created in 1987 the web agency Zeni-Corporation, listed on the Paris Stock Exchange and then bought up by Keyrus group in 2007. He then founded Drone Volt, a company specializing in the design, manufacturing and commercialization of civilian drones, which has been recording a triple digit growth since 2012. The company, of which he is a shareholder, is listed on Euronext Growth and operates in 30 countries. Dimitri Batsis is today a business angel and Chairman of Dimitri Batsis Investments.